TY - JOUR TI - Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates AU - Saunders, Kevin O. AU - Pardi, Norbert AU - Parks, Robert AU - Santra, Sampa AU - Mu, Zekun AU - Sutherland, Laura AU - Scearce, Richard AU - Barr, Maggie AU - Eaton, Amanda AU - Hernandez, Giovanna AU - Goodman, Derrick AU - Hogan, Michael J. AU - Tombacz, Istvan AU - Gordon, David N. AU - Rountree, R. Wes AU - Wang, Yunfei AU - Lewis, Mark G. AU - Pierson, Theodore C. AU - Barbosa, Chris AU - Tam, Ying AU - Shen, Xiaoying AU - Ferrari, Guido AU - Tomaras, Georgia D. AU - Montefiori, David C. AU - Weissman, Drew AU - Haynes, Barton F. T2 - npj Vaccines AB - The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of immunization against infectious diseases in preclinical studies, and are being tested for SARS-CoV-2 in humans. A critical question is how mRNA-LNP vaccine immunogenicity compares to that of traditional adjuvanted protein vaccines in primates. Here, we show that mRNA-LNP immunization compared to protein immunization elicits either the same or superior magnitude and breadth of HIV-1 Env-specific polyfunctional antibodies. Immunization with mRNA-LNP encoding Zika premembrane and envelope or HIV-1 Env gp160 induces durable neutralizing antibodies for at least 41 weeks. Doses of mRNA-LNP as low as 5 μg are immunogenic in macaques. Thus, mRNA-LNP can be used to rapidly generate single or multi-component vaccines, such as sequential vaccines needed to protect against HIV-1 infection. Such vaccines would be as or more immunogenic than adjuvanted recombinant protein vaccines in primates. DA - 2021/04/09/ PY - 2021 DO - 10.1038/s41541-021-00307-6 DP - www.nature.com VL - 6 IS - 1 SP - 1 EP - 14 LA - en SN - 2059-0105 UR - https://www.nature.com/articles/s41541-021-00307-6 Y2 - 2021/04/09/22:52:44 ER -